Blood Cancer Program
Making leading-edge hematologic therapies accessible to all Arizonans
About Our Program
The Hematologic Malignancy and Cellular Therapy Program at City of Hope® Cancer Center Phoenix focuses on breakthrough treatments for all hematologic malignancies, offering access to innovative therapies and clinical trials not available anywhere else in Arizona.
Our team of skilled physicians and advance practice providers focus on reducing treatment toxicity and improving patient outcomes using leading-edge transplant methods. Our program is structured to encourage collaboration through regularly scheduled tumor boards, where each patient is reviewed and benefits from the expertise of hematologic malignancy and transplant experts from across our national cancer care system. City of Hope has become known for:
- Extending curative bone marrow therapy (BMT) to more patients — With regimens that capitalize on graft versus tumor effect rather than on intense chemotherapy and radiation, this curative therapy can be available to more patients
- Breaking the age barrier for BMT candidacy — Older patients with lymphoblastic leukemia, acute myeloid leukemia, myelodysplasia and myeloproliferative disorders are evaluated for BMT like their younger counterparts, with the expectation of long-term cure of their bone marrow disorder.
- Leading the way in cellular therapies — At the forefront of the application of bispecific antibodies, City of Hope was a contributing organization to the first FDA-approved BiTE treatment and among the first to utilize CAR T-cell therapy as a bridge to stem cell transplant
Refer a Patient to City of Hope
We strive to offer a well-coordinated experience for our referring providers. Upon receiving your referral, our team will immediately begin processing the referral, with minimal work on your end.
Address
14200 West Celebrate Life Way
Goodyear, AZ 85338
Contact information
Phone: (623) 207-3241
Fax: (623) 932-8631
Email: referrals@coh.org
Institutional Distinctions
Delivering tomorrow's advances in cancer care to those who need them today
- One of the world's largest and most successful bone marrow and blood stem cell transplant programs
- More than 19,000 bone marrow and stem cell transplants performed and recognized as the only cancer center nationwide to exceed outcome expectations for patients for 15 consecutive years
- Instrumental in developing T-cell engager protocols, including the first FDA approved bispecific antibody treatment and the first to utilize CAR T-cell therapy as a bridge to stem cell transplant.
- First to offer CAR T trials targeting CD123 in acute myeloid leukemia and use CAR T cell therapy to treat patients with the rare disease blastic plasmacytoid dendritic cell neoplasm
- Expertise with rare lymphoma subtypes, including peripheral T cell lymphoma, double-hit B cell lymphomas and AIDS-related lymphomas
- The Center for International Blood and Marrow Transplant Research has ranked City of Hope as an “overperforming” transplant center
Dedicated Center for Hematologic Malignancies
The Hematologic Malignancy and Cellular Therapy Program offers a dedicated multidisciplinary team that blends innovative research discoveries with superior clinical treatments. As hematologic diseases may frequently be treated by multiple modalities, there is deliberate collaboration between physicians and advanced practice providers to optimize clinical outcomes. The result is improved outcomes for patients with various hematologic malignancies and other blood disorders.
Code Acute Leukemia™
When patients present to an ER with symptoms of acute leukemia, immediate evaluation and initiation of treatment is critical. We’ve developed a comprehensive process to help you expedite the transfer of these patients to our cancer center, where they can receive immediate specialized care with the urgency they deserve.
Our Code Acute Leukemia program offers:
- A single phone number to escalate care and initiate the transfer: (623) 207-3255
- Immediate peer-to-peer calls to provide clinical advice on how best to stabilize patients for transfer
- Real time verification of insurance benefits to address any insurance concerns
Code Acute Leukemia patients are transferred directly to our hematologic malignancy unit at our cancer center in Goodyear, Arizona, the only FACT-accredited center in the west valley.
Our Services & Offerings
At City of Hope, our physicians and clinical experts diagnose and treat a variety of types and stages of hematologic cancers, including relapsed or refractory disease.
Our Commitment to Clinical Excellence
Our Phoenix program offers a dedicated multidisciplinary team that blends innovative research discoveries with superior clinical treatments. The result is improved outcomes for patients with various blood cancers, blood abnormalities and other hematologic disorders. Additionally, our program is:
- Accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), a distinction which is given to facilities that meet the highest standards in clinical care for adult allogeneic and
autologous stem cell therapy, immune effector cell therapy, cell therapy product collection and cell therapy product processing. - Certified by the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative Certification Program, which is awarded to hospitals that demonstrate a commitment to quality
along nationally approved standards. - Accredited laboratory by the College of American Pathologists, including recognition for biorepository services for tissue collection, preparation, sampling and processing. Our hospital is among fewer than 100 CAP-accredited biorepository programs in the U.S
Dedication to Speed to Care
City of Hope Cancer Center and our outpatient cancer care locations are intentionally structured to maximize speed to care, with: